Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine Administration
Open Access
- 1 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesiology
- Vol. 114 (6), 1435-1445
- https://doi.org/10.1097/aln.0b013e318218a881
Abstract
Background Low-dose ketamine is used as analgesic for acute and chronic pain. It is metabolized in the liver to norketamine via cytochrome P450 (CYP) enzymes. There are few human data on the involvement of CYP enzymes on the elimination of norketamine and its possible contribution to analgesic effect. The aim of this study was to investigate the effect of CYP enzyme induction by rifampicin on the pharmacokinetics of S-ketamine and its major metabolite, S-norketamine, in healthy volunteers. Methods Twenty healthy male subjects received 20 mg/70 kg/h (n = 10) or 40 mg/70 kg/h (n = 10) intravenous S-ketamine for 2 h after either 5 days oral rifampicin (once daily 600 mg) or placebo treatment. During and 3 h after drug infusion, arterial plasma concentrations of S-ketamine and S-norketamine were obtained at regular intervals. The data were analyzed with a compartmental pharmacokinetic model consisting of three compartments for S-ketamine, three sequential metabolism compartments, and two S-norketamine compartments using the statistical package NONMEM® 7 (ICON Development Solutions, Ellicott City, MD). Results Rifampicin caused a 10% and 50% reduction in the area-under-the-curve of the plasma concentrations of S-ketamine and S-norketamine, respectively. The compartmental analysis indicated a 13% and 200% increase in S-ketamine and S-norketamine elimination from their respective central compartments by rifampicin. Conclusions : A novel observation is the large effect of rifampicin on S-norketamine concentrations and indicates that rifampicin induces the elimination of S-ketamine's metabolite, S-norketamine, probably via induction of the CYP3A4 and/or CYP2B6 enzymes.Keywords
This publication has 32 references indexed in Scilit:
- Response to Drs. Kapural and Stanton-HicksPain, 2010
- Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled studyPain, 2009
- Use of Human Microsomes and Deuterated Substrates: An Alternative Approach for the Identification of Novel Metabolites of Ketamine by Mass SpectrometryDrug Metabolism and Disposition, 2009
- Effects of norketamine enantiomers in rodent models of persistent painPharmacology Biochemistry and Behavior, 2008
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteersBiopharmaceutics & Drug Disposition, 2002
- Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms toN-Demethylation of Ketamine in Human Liver MicrosomesDrug Metabolism and Disposition, 2002
- A Size Standard for PharmacokineticsClinical Pharmacokinetics, 1996
- Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedationEuropean Journal of Drug Metabolism and Pharmacokinetics, 1990
- Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in manJournal of Pharmacokinetics and Biopharmaceutics, 1987